Inflammatory IL‐1β‐driven JNK activation in stage III melanoma

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Pigment Cell & Melanoma Research

• Publication date

  2015-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/pcmr.12348PMID 25546243
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The 2 Faces of JNK Signaling in Cancer.

  2013cited by this paper
• c-Jun N-Terminal Kinases Mediate a Wide Range of Targets in the Metastatic Cascade.

  2013cited by this paper
• Constitutive Aberrant Endogenous Interleukin-1 Facilitates Inflammation and Growth in Human Melanoma

  2011cited by this paper
• c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges.

  2010influential reference
• c-Jun N-terminal kinases as potential therapeutic targets

  2007cited by this paper
• Tumor iNOS predicts poor survival for stage III melanoma patients

  2006cited by this paper
• Chemical genetic analysis of the time course of signal transduction by JNK.

  2006cited by this paper
• Targeting JNK for therapeutic benefit: from junk to gold?

  2003cited by this paper

• Comparison of the Basal Cell Carcinoma (BCC) Tumour Microenvironment to Other Solid Malignancies

  2023cites this paper
• Anti-cancer effects of lucidadiol against malignant melanoma cells

  2021cites this paper
• IL-1 Signaling in Tumor Microenvironment.

  2020cites this paper
• The JNK Signaling Pathway in Inflammatory Skin Disorders and Cancer

  2020cites this paper
• Interleukin 32 expression in human melanoma

  2019cites this paper
• MiR-22 sustains NLRP3 expression and attenuates H. pylori-induced gastric carcinogenesis

  2018cites this paper